Damora Therapeutics (DMRA) Other Non-Current Liabilities (2024 - 2026)

Damora Therapeutics (DMRA) has 3 years of Other Non-Current Liabilities data on file, last reported at $5.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 10975.56% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 10975.56% YoY), and the FY2025 full-year result was $81000.0, up 88.37% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $5.0 million, up from $81000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $5.0 million in Q1 2026 and bottomed at $43000.0 in Q4 2024.
• The 3-year median for Other Non-Current Liabilities is $49000.0 (2025), against an average of $875166.7.
• The widest annual swing landed in 2025, when Other Non-Current Liabilities jumped 88.37%; it then surged 10975.56% in 2026.
• A 3-year view of Other Non-Current Liabilities shows it stood at $43000.0 in 2024, then surged by 88.37% to $81000.0 in 2025, then soared by 6053.09% to $5.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $5.0 million (Q1 2026), $81000.0 (Q4 2025), and $49000.0 (Q3 2025), per Business Quant data.

Peer Comparison